OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients

What is the purpose of this trial?

This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) for the treatment of urinary incontinence due to overactive bladder in pediatric patients between the ages of 12 to 17 years who have not been adequately managed with anticholinergics.

Participation Guidelines

Ages: 12 - 17 years

Gender: Both

Allergan Sales, Inc.

Start Date: 01/02/2015

End Date: 12/31/2018

Last Updated: 02/22/2018

Study HIC#: 1409014633

Get Involved

For more information about this study, contact:
Kristin DeFrancesco
+1 203-785-3852

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Adam Benjamin Hittelman

Principal Investigator